GRI Bio, Inc. (NASDAQ:GRI) Short Interest Down 96.6% in August

GRI Bio, Inc. (NASDAQ:GRI) was the target of a significant decrease in short interest in the month of August. As of August 15th, there was short interest totalling 2,800 shares, a decrease of 96.6% from the July 31st total of 83,400 shares. Based on an average trading volume of 495,800 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.1% of the company’s shares are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GRI Bio stock. Armistice Capital LLC acquired a new stake in GRI Bio, Inc. (NASDAQ:GRI) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 50,207 shares of the company’s stock, valued at approximately $96,000. Armistice Capital LLC owned 9.23% of GRI Bio at the end of the most recent quarter. Hedge funds and other institutional investors own 33.95% of the company’s stock.

GRI Bio Stock Performance

GRI Bio stock traded up 0.07 during mid-day trading on Tuesday, hitting 0.58. The company’s stock had a trading volume of 950,536 shares, compared to its average volume of 227,415. GRI Bio has a one year low of 0.40 and a one year high of 188.37. The company has a 50 day moving average of 1.33 and a 200-day moving average of 5.48.

About GRI Bio

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.